<SEC-DOCUMENT>0001096906-24-001590.txt : 20240725
<SEC-HEADER>0001096906-24-001590.hdr.sgml : 20240725
<ACCEPTANCE-DATETIME>20240725144423
ACCESSION NUMBER:		0001096906-24-001590
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240725
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240725
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		241141348

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20240725.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20240725" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D240725" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D240725" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20240725.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D240725">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-07-25</i:startDate>
<i:endDate>2024-07-25</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D240725" escape="true" id="ixv-342">8-K</ix:nonNumeric></b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D240725" format="ixt:date-monthname-day-year-en" id="ixv-343">July 25, 2024</ix:nonNumeric></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D240725" escape="true" id="ixv-344">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D240725" format="ixt-sec:stateprovnameen" id="ixv-345">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D240725" escape="true" id="ixv-346">000-12575</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D240725" escape="true" id="ixv-347">87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D240725" escape="true" id="ixv-348">7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"> <span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D240725" escape="true" id="ixv-349">Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D240725" format="ixt-sec:stateprovnameen" id="ixv-350">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D240725" escape="true" id="ixv-351">84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b>Phone: </b><b>(</b><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="D240725" escape="true" id="ixv-352">801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D240725" escape="true" id="ixv-353">566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:12pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D240725" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D240725" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D240725" format="ixt-sec:boolballotbox" id="ixv-356">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D240725" format="ixt-sec:boolballotbox" id="ixv-357">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:3.76%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:96.24%"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D240725" format="ixt-sec:boolballotbox" id="ixv-358">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated July 25, 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:72pt">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated July 25, 2024.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Dated: &#160;July 25, 2024</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND FORWARD-LOOKING STATEMENTS RELATING TO 2024 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 25, 2024.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024</B></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:11pt Times New Roman;margin:0'>Contact: Brian Koopman (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:11pt Times New Roman;margin:0'>July 25, 2024</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;As previously projected, Utah Medical Products, Inc. [Nasdaq: UTMD] realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In brief, consolidated total 2Q 2024 revenues were $2,466 (19.2%) lower than in 2Q 2023, with 1H 2024 revenues $3,646 (14.4%) lower than in 1H 2023. &nbsp;The decline in sales in three categories explain more than the total consolidated sales decline. &nbsp;WW in the table below = &#8220;worldwide&#8221;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:42.84%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenue Category</FONT></P>
</TD><TD valign=top style=width:28.54%><P align=center style='font:11pt Times New Roman;margin:0'>Portion of 2Q Lower Total <FONT style='border-bottom:1px solid #000000'>UTMD Sales</FONT></P>
</TD><TD valign=top style=width:28.62%><P align=center style='font:11pt Times New Roman;margin:0'>Portion of 1H Lower Total <FONT style='border-bottom:1px solid #000000'>UTMD Sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:42.84%><P style='font:11pt Times New Roman;margin:0'>WW PendoTECH OEM</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:28.54%><P align=center style='font:11pt Times New Roman;margin:0'>70%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:28.62%><P align=center style='font:11pt Times New Roman;margin:0'>76%</P>
</TD></TR>
<TR><TD valign=top style=width:42.84%><P style='font:11pt Times New Roman;margin:0'>China BPM Distributor</P>
</TD><TD valign=top style=width:28.54%><P align=center style='font:11pt Times New Roman;margin:0'>21%</P>
</TD><TD valign=top style=width:28.62%><P align=center style='font:11pt Times New Roman;margin:0'>12%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:42.84%><P style='font:11pt Times New Roman;margin:0'>WW Filshie Clip System</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:28.54%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16%</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:28.62%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>25%</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:42.84%><P align=right style='font:11pt Times New Roman;margin:0'>Total:</P>
</TD><TD valign=top style=width:28.54%><P align=center style='font:11pt Times New Roman;margin:0'>107%</P>
</TD><TD valign=top style=width:28.62%><P align=center style='font:11pt Times New Roman;margin:0'>113%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In other words, aggregated consolidated sales in all other sales categories were higher when comparing 2024 to 2023 in both periods. Please see more details explaining revenue results below.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Despite the significantly lower sales, UTMD achieved profit margins in all income categories similar to those of the prior year&#8217;s same periods:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:47.94%><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:13.18%><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>2Q 2024</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style='width:13.18%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>2Q 2023</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style='width:13.16%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>1H 2024</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style=width:12.52%><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>1H 2023</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.94%><P style='font:11pt Times New Roman;margin:0'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.18%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>60.1%</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.18%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>60.1% </P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.16%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>59.9%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.52%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>61.4%</P>
</TD></TR>
<TR><TD valign=top style=width:47.94%><P style='font:11pt Times New Roman;margin:0'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.1%</P>
</TD><TD valign=top style='width:13.18%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>34.4%</P>
</TD><TD valign=top style='width:13.16%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.7%</P>
</TD><TD valign=top style=width:12.52%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>34.9%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.94%><P style='font:11pt Times New Roman;margin:0'>Income B4 Tax Margin (EBT/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.18%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>40.5%</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.18%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>40.2%</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.16%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>41.4%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.52%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>40.5%</P>
</TD></TR>
<TR><TD valign=top style=width:47.94%><P style='font:11pt Times New Roman;margin:0'>Net Income Margin &nbsp;(NI/ sales)<I>:</I></P>
</TD><TD valign=top style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.2%</P>
</TD><TD valign=top style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>32.6%</P>
</TD><TD valign=top style=width:13.16%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>34.1%</P>
</TD><TD valign=top style=width:12.52%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.1%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>A summary of the change in income statement results, according to U.S. Generally Accepted Accounting Principles (US GAAP), follows:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:48.44%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>2Q</P>
</TD><TD valign=top style=width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>1H</P>
</TD></TR>
<TR><TD valign=top style=width:48.44%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(April &#8211;&nbsp;June)</FONT></P>
</TD><TD valign=top style=width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(January-June)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.44%><P style='font:11pt Times New Roman;margin:0'>Revenues (Sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(19%)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(14%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.44%><P style='font:11pt Times New Roman;margin:0'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(19%)</P>
</TD><TD valign=top style=width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(16%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.44%><P style='font:11pt Times New Roman;margin:0'>Operating Income (OI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(22%)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(17%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.44%><P style='font:11pt Times New Roman;margin:0'>Income Before Tax (EBT):</P>
</TD><TD valign=top style=width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(19%)</P>
</TD><TD valign=top style=width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(12%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.44%><P style='font:11pt Times New Roman;margin:0'>Net Income (NI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(18%)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(12%)</P>
</TD></TR>
<TR><TD valign=top style=width:48.44%><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:25.04%><P align=center style='font:11pt Times New Roman;margin:0'>(15%)</P>
</TD><TD valign=top style=width:26.52%><P align=center style='font:11pt Times New Roman;margin:0'>(11%)</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>The percentage decline in 2Q consolidated revenues was greater than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer increased from $1,046 in 1Q 2024 to $1,732 in 2Q 2024. UTMD now expects a similar magnitude of decline in the last two quarters of the year as in 2Q 2024, resulting in $6 million lower sales to this OEM customer for the year as a whole. &nbsp;UTMD remarkably achieved the same GP margin in 2Q 2024 as in 2Q 2023 despite 19% lower sales after making timely reductions in manufacturing expenses. The Company believes that the reductions were made without sacrificing critical resources needed for longer term growth. &nbsp;OI declined more than GP due to $689 higher 1H 2024 U.S. litigation costs which are included in Operating Expense per US GAAP. Higher non-operating income brought the decline in EBT to be in line with the decline in sales. &nbsp;A lower estimated income tax provision rate mitigated the decline in NI, and significant share repurchases during 1H 2024 helped further reduce the decline in EPS relative to the sales decline. &nbsp;Please see the income statements on the last page of this report.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s June 30, 2024 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $89.2 million on June 30, 2024 compared to $92.9 million on December 31, 2023. &nbsp;The June 30, 2024 cash balance resulted after paying $2.2 million in cash dividends to stockholders, repurchasing $9.4 million of its common stock, increasing non-cash working capital by $0.5 million (including reducing current liabilities by $0.8 million) and making $0.1 million in capital expenditures during 1H 2024. &nbsp;Please see the balance sheets on the last page of this report.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 2Q 2024 UTMD worldwide (WW) sales in USD terms were $2,466 (19.2%) lower than in 2Q 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were $1,732 (77.3%) lower in 2Q 2024 compared to 2Q 2023. (There were no Ireland sales to PendoTech in 2Q 2024 compared to $608 in 2Q 2023.) &nbsp;New orders received from PendoTECH scheduled for the 2H 2024 have been minimal, resulting in a current backlog for WW PendoTECH shipments during the remainder of 2024 of approximately $450. As WW PendoTECH shipments in 2H 2023 were $3,798, UTMD expects that, without any new orders, 3Q and 4Q 2024 shipments, consistent with 2Q 2024, will also each be about $1.7 million lower as in the same periods in 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since they tend to order large quantities at a time in order to minimize transit and other logistical costs. &nbsp;The second major revenue decline category, which was also as projected in UTMD&#8217;s 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China. This customer consistently places calendar year fixed orders with UTMD. &nbsp;In 2Q 2024, sales were $502 (39.3%) lower due to an extra shipment in 2Q 2023 compared to 2Q 2024. &nbsp;Unlike 2Q 2024, 3Q 2024 shipments will not be lower than 3Q 2023 to this distributor, but 4Q 2024 shipments are scheduled to be $1.2 million lower.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>With a high level of uncertainty, UTMD projected maintaining Filshie Clip System device (Filshie) sales in 2024 similar to 2023. &nbsp;This was the third major category responsible for lower sales. &nbsp;WW consolidated Filshie sales in 2Q 2024 were $405 (12.8%) lower than in 2Q 2023. &nbsp;Domestic Filshie sales were $165 (13.9%) lower, OUS direct sales were $149 (10.0%) lower and OUS distributor sales were $91 (19.1%) lower.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In sum, the 2Q 2024 decline in sales from the three categories above compared to 2Q 2023 was $2,639, which is obviously greater than the $2,466 decline in total consolidated sales.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>In 2Q 2024 compared to 2Q 2023, outside the U.S. (OUS) sales were $1,280 (21.9%) lower and U.S. domestic sales were $1,186 (16.9%) lower.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The portion of OUS sales invoiced in foreign currencies in USD terms were 35% of total WW consolidated 2Q 2024 sales compared to 33% in 2Q 2023. <A name=_Hlk172127203 />The net impact of changes in period-to-period foreign currency exchange (FX) rates was negligible. The average USD FX rates reduced 2Q 2024 total consolidated sales $23 (0.2%) for sales invoiced in foreign currencies. <A name=_Hlk108176647 />Actually, a stronger GBP by itself added $6. &nbsp;The EUR, CAD and AUD were weaker. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2024 and 2Q 2023 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>2Q <BR><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>2Q<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2615</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2531</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+0.7%</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0752</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0845</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( 0.9%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6594</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6700</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( 1.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7308</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7449</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( 1.9%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The $23 weighted average unfavorable impact on 2Q 2024 foreign currency OUS sales was 0.6%. &nbsp;In constant currency terms, foreign currency sales in 2Q 2024 were 21.5% lower than in 2Q 2023. &#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total OUS sales in 2Q 2024 were $4,569 compared to $5,849 in 2Q 2023. OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Direct to end-user OUS 2Q 2024 sales in USD terms (including the impact of FX rate differences) were 8.3% higher in Ireland with the EUR FX rate down about 0.9%, 12.3% lower in Canada with the CAD FX rate down 1.9%, 13.1% higher in the UK with the GBP FX rate up 0.7%, 9.6% lower in Australia/New Zealand with the AUD FX rate down 1.6%, and 25.5% lower in France with the EUR FX rate down only 0.9%. USD-denominated sales to OUS distributors were 30.7% lower in 2Q 2024 than in 2Q 2023 because Ireland sales to PendoTECH as well as sales to UTMD&#8217;s BPM device distributor in China are in this category.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 2Q 2024 were $5,831 compared to $7,017 in 2Q 2023. &nbsp;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S.  Direct non-Filshie device sales, representing 63% of total domestic sales, were about the same, just $8 (0.2%) lower in 2Q 2024 than in 2Q 2023. Domestic OEM sales, representing 20% of total domestic sales, in total were $1,013 (47.0%) lower. In this category, U.S. PendoTECH sales were $1,124 lower. &nbsp;Domestic Filshie device sales, representing 17% of total domestic sales, were $165 (13.9%) lower in 2Q 2024 compared to 2Q 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1H 2024 UTMD WW sales in USD terms were $3,646 (14.4%) lower than in 1H 2023.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were $2,788 (57.5%) lower in 1H 2024 compared to 1H 2023. Ireland sales alone to PendoTech in 1H 2024 were $919 lower than in 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The second major revenue decline category, which was also as projected in UTMD&#8217;s 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China. In 1H 2024, sales were $415 (20.7%) lower due to an extra shipment in 2Q 2023 compared to 2Q 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>With a high level of uncertainty, UTMD projected maintaining Filshie Clip System device (Filshie) sales in 2024 similar to 2023. &nbsp;This was the third major category responsible for lower 1H sales. &nbsp;WW consolidated Filshie sales in 1H 2024 were $918 (14.2%) lower than in 1H 2023. &nbsp;Domestic Filshie sales were $362 (14.8%) lower, OUS direct sales were $266 (8.8%) lower and OUS distributor sales were $290 (29.0%) lower.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In sum, the 1H 2024 decline in sales from the three categories above compared to 1H 2023 was $4,111, which is obviously greater than the $3,646 decline in total consolidated sales. In 1H 2024 compared to 1H 2023, OUS sales were $1,466 (13.1%) lower and U.S. domestic sales were $2,180 (15.3%) lower.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total OUS sales in 1H 2024 were $9,718 compared to $11,184 in 1H 2023. The portion of OUS sales invoiced in foreign currencies in USD terms were 33% of total WW consolidated 1H 2024 sales compared to 31% in 1H 2023 because Ireland sales to PendoTECH were invoiced in USD. The net impact of changes in period-to-period foreign currency exchange (FX) rates was negligible. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1H 2024 and 1H 2023 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1H<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1H<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2646</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2329</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 2.6%</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0787</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0819</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;0.3%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6586</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6774</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;2.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7362</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7419</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;0.8%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The weighted-average FX rate positive impact on 1H 2024 foreign currency OUS sales was 0.2%. In constant currency terms, foreign currency sales in 1H 2024 were 8.3% lower than in 1H 2023. &nbsp;In constant currency terms, 1H 2024 total OUS sales were 13.3% lower than in 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Direct to end-user OUS 1H 2024 sales in USD terms (including the impact of FX rate differences) were 20% higher in Ireland with the EUR FX rate about the same, 10% lower in Canada with the CAD FX rate down 1%, 8% higher in the UK with the GBP FX rate 3% higher, 17% lower in Australia/New Zealand with the AUD FX rate down 3%, and 20% lower in France with the EUR FX rate about the same as in 1H 2023. USD-denominated sales to OUS distributors (excluding PendoTECH) were 7% lower in 1H 2024 than in 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 1H 2024 were $12,023 compared to $14,202 in 1H 2023. Direct non-Filshie device sales, representing 60% of total domestic sales, were $114 (1.6%) lower in 1H 2024 than in 1H 2023. Domestic OEM sales, representing 23% of total domestic sales, were $1,704 (38.2%) lower. In this category, since U.S. PendoTECH sales were $1,860 lower, other U.S. OEM sales were obviously $156 higher. Domestic Filshie device sales, representing 17% of total domestic sales, were $362 (14.8%) lower in 1H 2024 compared to 1H 2023.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the cost of goods sold (CGS), comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers, from revenues. CGS is divided into three categories: direct labor, raw materials and manufacturing overhead (MOH). &nbsp;Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. &nbsp;MOH contains many fixed costs consistent with the Company&#8217;s infrastructure, for example, supervision and engineering personnel.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s 2Q 2024 GP was $1,486 (19.2%) lower than in 2Q 2023 due to being able to achieve the same GP margin (GP divided by sales, GPM) with 19.2% lower sales. GP in 1H 2024 was $2,563 (16.4%) lower than in 1H 2023 with sales 14.4% lower, as UTMD&#8217;s 1Q 2024 GPM was diluted from manufacturing overhead expenses which had not yet been reduced in proportion to sales. The 1H 2024 GPM was 59.9% compared to 61.4% in 1H 2023. &nbsp;UTMD&#8217;s 2024 GPMs were consistent with long-term profitability goals.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>With lower sales and consequent lower absorption of fixed MOH costs, a higher than expected average GPM was achieved through several means; 1) a favorable product sales mix, i.e. lower sales to UTMD&#8217;s China distributor at UTMD&#8217;s lowest GPM, 2) a direct labor productivity improvement as the least experienced production workers were furloughed, 3) reduction of some production supervision and management, 4) relief in marginal costs of some raw materials, 5) substantially lower incoming freight costs from raw material vendors, and 6) a reduction in intercompany finished goods inventory which freed up reserved gross profit.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. &nbsp;OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 2Q 2024 of $3,438 was $987 (22.3%) lower compared to 2Q 2023 OI of $4,425. &nbsp;<A name=_Hlk172206782 />The lower OI <A name=_Hlk140777717 />was the result of $1,486 lower GP offset in part by $499 lower OE, explained below. UTMD&#8217;s 2Q 2024 OI Margin (OI as a percentage of sales) remained a healthy 33.1%.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 1H 2024 was $7,321 compared to $8,864 in 1H 2023, a decrease of $1,542 (17.4%), remaining a healthy 1H 2024 OI margin of 33.7%. &nbsp;The lower OI was the result of $2,563 lower GP offset in part by $1,020 lower OE, explained below.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The following table summarizes OE in 2Q and 1H 2024 compared to the same periods in 2023 by OE category:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:12.62%><P style='font:11pt Times New Roman;margin:0'>OE <FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:11.44%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:12.62%><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>$ 546</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.3</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 405</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.2</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 958</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.4</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 792</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.1</P>
</TD></TR>
<TR><TD valign=bottom style=width:12.62%><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=bottom style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>2,014</P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,775</P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>21.6</P>
</TD><TD valign=bottom style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,219</P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,648</P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>22.3</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:12.62%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;255</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;2.4</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;133</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.0</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;520</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;2.4</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;277</FONT></P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD></TR>
<TR><TD valign=bottom style=width:12.62%><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=bottom style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>2,815</P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>27.1</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,313</P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>25.8</P>
</TD><TD valign=bottom style='width:11.12%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,697</P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>26.2</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>6,717</P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>26.5</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>S&amp;M OE were $141 and $165 higher in 2Q 2024 and 1H 2024 compared to the same periods in 2023 respectively. &nbsp;UTMD in the U.S. is self-insured for its employee health plan. &nbsp;One employee&#8217;s 2Q medical claim that did not occur in the prior year explains about $100 of the difference in both periods. An earlier </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>timing of trade shows in 2Q than in the prior year together with higher travel expenses explains about another $20 of the 2Q and 1H 2024 differences to same periods in 2023. The remaining differences are primarily due to higher salaries for existing S&amp;M employees in 2024 compared to 2023 worldwide. The impact of differences in FX rates on foreign subsidiary S&amp;M expenses was insignificant (see below). &nbsp;Because of lower sales in addition to the higher expenses, S&amp;M expenses as a percentage of sales increased substantially to 5.3% in 2Q 2024 from 3.2% in 2Q 2023, and to 4.4% of sales in 1H 2024 from 3.1% in 1H 2023.</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>G&amp;A expenses dominate UTMD&#8217;s OE, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System and the expenses of current litigation in the U.S. &nbsp;A segmentation of USD-denominated G&amp;A expenses follows:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>$ 501</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 4.8</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 498</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 3.9</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$1,005</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.6</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;981</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.9</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;-</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>8.6</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;-</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2,210</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.7</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;173</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;163</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;360</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;327</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>U.S. Litigation</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>  &nbsp;635 &nbsp;</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>6.1</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;280 &nbsp;</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2.2</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;1,378</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>6.3</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;689</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.7</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; US:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;557</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5.4</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;588</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4.6</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;1,158</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5.3</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;1,150</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.5</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;92</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;69</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;186</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;153</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;24</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;35</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;66</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;32</FONT></P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp; 37</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;66</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp; 69</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>2,014</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,775</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>21.6</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4,219</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,648</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>22.2</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated G&amp;A expenses in 2Q 2024 were $761 lower, and in 1H 2024 were $1,429 lower than in the same periods in 2023. &nbsp;The amortization of IIA associated with UTMD purchasing CooperSurgical Inc&#8217;s exclusive U.S. distribution and use of intellectual property rights in 2019 was fully amortized in late 2023. &nbsp;In the 1H of 2024, this reduced OE by $1,105 per calendar quarter compared to 1H 2023. &nbsp;Offsetting that significant G&amp;A expense reduction was an increase in U.S. litigation expenses related to the Filshie Clip System of $355 in 2Q 2024 compared to 2Q 2023, and $689 in 1H 2024 compared to 1H 2023. &nbsp;The remaining IIA amortization &#8211;&nbsp;UK from the 2011 acquisition of Femcare only varied as a result of the change in the GBP FX rate, as the amortization expense in GBP was the same in both periods. All other G&amp;A expenses in the aggregate were similar in both periods.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The differences in period-to-period R&amp;D expenses were due to extensive outside material validation studies in 2024 required by biopharmaceutical industry manufacturers for devices used in their manufacturing processes. Since all R&amp;D in 2024 was carried out in the U.S., there was no FX rate impact.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The impact of differing FX rates in 2024 and 2023 on OE expressed in USD was negligible. The EUR, AUD and CAD were all slightly weaker, but an average stronger GBP helped increase foreign currency OE when converted to USD by a net $2 in 2Q 2024 and $30 in 1H 2024. The following table summarizes &#8220;constant currency&#8221; OE in 2Q and 1H 2024 compared to the same periods in 2023 by OE category:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:14.72%><P style='font:11pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0'>2Q 2024 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:5.48%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=bottom style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1H 2024 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=bottom style=width:11.06%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:14.72%><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:13.18%><P align=center style='font:11pt Times New Roman;margin:0'>$ 547</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:5.48%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 405</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 958</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 792</P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.06%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:14.72%><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=bottom style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0'>2,011</P>
</TD><TD valign=bottom style='width:5.48%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,775</P>
</TD><TD valign=bottom style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,189</P>
</TD><TD valign=bottom style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,648</P>
</TD><TD valign=bottom style=width:11.06%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=background-color:#CCEEFF;width:14.72%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:13.18%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;255</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:5.48%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;133</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;520</FONT></P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;277</FONT></P>
</TD><TD valign=bottom style=background-color:#CCEEFF;width:11.06%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:14.72%><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=bottom style=width:13.18%><P align=center style='font:11pt Times New Roman;margin:0'>2,813</P>
</TD><TD valign=bottom style='width:5.48%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,313</P>
</TD><TD valign=bottom style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,667</P>
</TD><TD valign=bottom style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>6,717</P>
</TD><TD valign=bottom style=width:11.06%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 2Q 2024 EBT was $4,211 (40.5% of sales) compared to $5,172 (40.2% of sales) in 2Q 2023. Consolidated 1H 2024 EBT was $9,010 (41.4% of sales) compared to $10,291 (40.5% of sales) in 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms on June 30, 2024; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Starting in 2024 for UTMD, there is an additional excise tax included in NOE: a stock repurchase excise tax included in the so-called &#8220;Inflation Reduction Act of 2022&#8221;. &nbsp;Although the new 1% tax on the aggregate fair market value of share repurchases made in 2023 applies, UTMD did not repurchase shares in 2023. After the U.S. Treasury and IRS announced regulations governing the stock repurchase excise tax in 2Q 2024, UTMD begins reporting the NOE in its 2Q 2024 income statement for the $9,393 in share repurchases made during 1H 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Net NOI is NOI minus NOE. &nbsp;Net NOI in 2Q 2024 was $773 compared to $747 net NOI in 2Q 2023. Net NOI in 1H 2024 was $1,688 compared to $1,427 in 1H 2023. NOI in 2Q 2024 was reduced by a $94 excise tax on share repurchases. In 1H 2024 compared to 1H 2023, UTMD Ltd in Ireland received EUR 98 less rental income on its underutilized property. &nbsp;Remeasured foreign currency balances generated about $8 more in net NOI in 1H 2024 compared to 1H 2023. &nbsp;With higher cash balances in 2024, UTMD received approximately $345 more in 1H interest income compared to 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain high level financial performance during a challenging time.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2024 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $4,942 (47.5% of sales) compared to $6,996 (54.4% of sales) in 2Q 2023. &nbsp;Adjusted consolidated EBITDA at $10,489 (48.3% of sales) in 1H 2024 was 24.6% lower than the $13,916 (54.8% of sales) in 1H 2023. Approximately 75% of the lower EBITDA was due to lower GP. The rest was due primarily to higher litigation expenses and no CSI IIA amortization expense. Adjusted consolidated trailing twelve months&#8217; (TTM) EBITDA was $23,208 as of June 30, 2024.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>$ 4,211</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 5,172</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$9,010</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'> $10,291</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>172</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>155</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>327</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>310</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>501</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>498</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,005</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>981</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>2,211</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>18</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>16</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>52</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>50</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>130</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>100</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.9%><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:47.9%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:11.48%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(2)</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(1)</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:47.9%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.48%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,942</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$6,996</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$10,489</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$13,916</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><A name=_Hlk140828510 />NI in 2Q 2024 of $3,453 (33.2% of sales) was 17.8% lower than the NI of $4,200 (32.6% of sales) in 2Q 2023. &nbsp;<A name=_Hlk172296323 />The $747 lower 2Q NI was due to $987 lower OI combined with $27 higher net NOI, and a slightly lower average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 2Q 2024 was 18.0% compared to 18.8% in 2Q 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1H 2024 of $7,409 (34.1% of sales) was 11.9% lower than the NI of $8,414 (33.1% of sales) in 1H 2023. &nbsp;The $1,005 lower 1H NI was due to $1,542 lower OI combined with $261 higher net NOI, and a lower average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 1H 2024 was 17.8% compared to 18.2% in 1H 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Except for the UK, in which the corporate income tax rate changed to 25% from 19% on April 1, 2023, the basic corporate income tax rates in each of the sovereignties were the same as in the prior year.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 2Q 2024 were $0.978 compared to diluted EPS of $1.154 in 2Q 2023, a 15.3% decrease. Diluted EPS in 1H 2024 were $2.070 compared to diluted EPS of $2.313 in 1H 2023, a 10.5% decrease. The decreases in EPS were lower than the decreases in NI as a result of fewer diluted shares.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted shares were 3,531,572 in 2Q 2024 compared to 3,638,566 in 2Q 2023. &nbsp;Diluted shares were 3,579,435 in 1H 2024 compared to 3,637,715 in 1H 2023. The lower diluted shares in both periods of 2024 were the result of shares repurchased during 1H 2024, offset by employee options exercised and a dilution factor for unexercised options just in 2023. Because the average exercise price of employee options was higher than the ending market price of the stock in 2Q 2024, the number of shares added as a dilution factor in 2Q 2024 was zero compared to 10,288 in 2Q 2023. For the same reason, the number of shares added as a dilution factor in 1H 2024 was zero compared to 9,660 in 1H 2023. The number of shares used for calculating EPS in both years was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares, plus dilution in 2023 from unexercised employee options.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Outstanding shares at the end of 2Q 2024 were 3,498,902 compared to 3,629,525 at the end of calendar year 2023. The difference was due to 7,592 shares added from employee option exercises during 1H 2024 and 138,215 shares subtracted from repurchases in 1H 2024. Share repurchases in 2Q 2024 were 95,107 </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>shares at an average price of $67.33. &nbsp;Share repurchases in 1H 2024 were 138,215, as stated above, at an average price of $67.96. &nbsp;The total cost of repurchasing shares in 1H 2024 was $9,393,466. For comparison, outstanding shares were 3,628,988 at the end of 2Q 2023. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The total number of outstanding unexercised employee and outside director options at June 30, 2024 was 73,497 at an average exercise price of $77.01, including shares awarded but not yet vested. &nbsp;This compares to 66,025 unexercised option shares at the end of 2Q 2023 at an average exercise price of $73.78/ share, including shares awarded but not vested. No employee options have been awarded in 2024. &nbsp;Non-qualified option awards totaling 19,000 shares were made to 48 employees in October 2023 at an exercise price of $77.07.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD paid $1,081 ($0.300/share) in dividends to stockholders in 2Q 2024 compared to $1,070 ($0.295/ share) paid in 2Q 2023. <A name=_Hlk140832217 />The dividends paid to stockholders during 2Q 2024 were 31% of NI. UTMD paid $2,170 ($0.300/share) in dividends to stockholders in 1H 2024 compared to $2,140 ($0.295/ share) paid in 1H 2023. The dividends paid to stockholders during 1H 2024 were 29% of NI.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 2Q 2024 was $66.81, down 6.0% from the closing price of $71.11 at the end of 1Q 2024, and down 20.7% from the closing price of $84.22 at the end of 2023. &nbsp;The closing share price one year ago at the end of 2Q 2023 was $93.20.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>At June 30, 2024 compared to the end of 2023, UTMD&#8217;s cash and investments balance declined only $3,650 to $89,219 despite use of $9,393 cash for share repurchases, $2,170 cash for dividends to stockholders, and $132 cash for capital equipment purchases. At June 30, 2024, net Intangible Assets decreased to 13.5% of total consolidated assets from 16.2% on June 30, 2023. UTMD&#8217;s strong 26.0 current ratio at June 30, 2024 was higher than the 22.6 current ratio at December 31, 2023 as a result of favorable 1H 2024 working capital changes exceeding the negative impact of reducing cash. The average age of trade receivables was 32 days from date of invoice at June 30, 2024 compared to 24 days at December 31, 2023, based on the most recent calendar quarter of sales. Average inventory turns declined to 1.8 in 2Q 2024 compared to 2.2 for the last quarter of 2023 due primarily to a decline in sales activity, as inventory balances declined $525. Accrued liabilities declined by $836.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2024 compared to the end of calendar year 2023 and the end of 2Q 2023 were</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-24</FONT></P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-23</FONT></P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-23</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>1.26371</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.27386</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(0.8%)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.27084</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>(0.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>1.07109</P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.10593</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(3.2%)</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.09178</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>(1.9%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>0.66742</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.68248</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(2.2%)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.66614</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>0.2%</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>0.73068</P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.75733</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(3.5%)</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.75547</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>(3.3%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Financial ratios as of June 30, 2024 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 26.0&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 2Q 2024 sales activity) = 32&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 2Q 2024 CGS) = 1.8&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2024 YTD ROE (before dividends) = 12%&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Second Quarter (three months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:39.4%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:18.94%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=top style=width:19.74%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style=width:21.92%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:39.4%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.94%><P align=right style='font:10pt Times New Roman;margin:0'>$ 10,400</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.74%><P align=right style='font:10pt Times New Roman;margin:0'>$ 12,866</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.92%><P align=center style='font:10pt Times New Roman;margin:0'>(19.2%)</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>6,253</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,739</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(19.2%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,438</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,425</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(22.3%)</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,211</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,172</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(18.6%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,453</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,200</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(17.8%)</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 0.978</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$1.154</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(15.3%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,532</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,639</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Half (six months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:37.76%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>$ 21,740</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>$ 25,386</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>(14.4%)</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>13,018</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>15,581</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(16.4%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,321</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>8,864</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(17.4%)</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,010</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>10,291</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(12.5%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,409</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>8,414</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(11.9%)</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.070</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.313</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(10.5%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,579</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,637</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2024</FONT></P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2024</FONT></P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2023</FONT></P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>$89,219</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>$93,808</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>$92,868</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>$84,619</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>3,668</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>3,591</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>3,391</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>3,603</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>9,058</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>9,240</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>9,582</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>10,118</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>377</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>510</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>428</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>467</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>102,322</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>107,149</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>106,269</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>98,807</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>10,194</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>10,266</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>10,552</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>10,541</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>17,516</FONT></P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,026</FONT></P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,637</FONT></P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>21,127</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>$130,032</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>$135,441</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>$135,458</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>$130,475</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>834</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>998</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>769</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>1,336</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:18pt'>419</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,547</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,918</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,383</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,389</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,939</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,474</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$4,710</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,144</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>860</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>986</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>1,120</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>1,370</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>275</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>285</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>295</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>315</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>1,256</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>208</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>256</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>322</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>628</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>124,052</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>127,742</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>128,313</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>121,762</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>$130,032</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>$135,441</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>$135,458</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>$130,475</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20240725_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240725.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20240725_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20240725_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240725.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20240725.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VEFT4KDF]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20240725' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20240725' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2023'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240725_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240725_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240725_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd' namespace='http://xbrl.sec.gov/dei/2023'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140546729478624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jul. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MBW7Y6/_7>CCP    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ BW7Y6)E<G",0!@  G"<  !,
M ( !S@$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "+=?E8_K@?
M+NX#  "?#@  &               @($/"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ BW7Y6)^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  DQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20240725.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20240725.htm">utmd-20240725.htm</File>
    <File>utmd-20240725.xsd</File>
    <File>utmd-20240725_def.xml</File>
    <File>utmd-20240725_lab.xml</File>
    <File>utmd-20240725_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20240725.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20240725",
   "dts": {
    "inline": {
     "local": [
      "utmd-20240725.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20240725.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20240725_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20240725_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20240725_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D240725",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240725.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240725",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240725.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20240725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001096906-24-001590-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-24-001590-xbrl.zip
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M&,=?KW]%KO>".ZDAT*Y;6ZV=&*43:K>BPJV[.YTFDQBPZMC(=@K\]V?G1T?
M#]UT5RMY4R#^QGZ^GR>Q\R3IN_?+F'J/6$C"V7FCW6PU/,Q"'A$V/6\0R?V3
MD^-3O]UX?['W[A??]P:"1TF((V^\\GJ7'SMW,B$*>Y)/U ()?.!UHD?$C*#+
MXWFBL/#ZC/%'I/0 \D#_")L'NFV^$F0Z4]YOW=^]PU;KQ#]L';[V_AX,OEX?
M?[Q_^Z9]T_K2NQJ]OKZ\^J?I+1:+)HZF2*2C-4,>>[ZO(Z*$/9R9/V,DL:>M
M,'F^/U-J?A8$9I_E6- F%]- #W$4%,+]O5>O4NW94I*2?G%4J-O!UT\WPW"&
M8^03)I7QE.XGR9E,-]_P,#7U P-ZH,+\\@N9;S;Y[4/_J-U<RNA[F!-"GT9)
M%)K%.#(, L.L]?;P^+O2=/5S!+;VR!FT3T]/@[1U3:P[B]23>KWOXR!K+(O)
MCEB>J%[LO<H2*3C%=WCBF<\_[OH[+0=&%)!(?+OD81)CIHK/#HMZ3!&UZK,)
M%W&:HWTO=7*F5G-\OB])/*>XV#83>'*^GZ@X\HO.#?U??[COX,G 7&"I5>GF
M&[VA-"I>*LPB'!7C&@/_IT4=11X&Y>'ZR UJCE0N&NN&&V9@621Q@N0XS4PB
M_2E"<Q/#48"IDL46P^8HY9)O^#;2AC[HKA\Z8ZD$"E71/T5C3,\;L"[X+Z%*
M'#:G_#&(,,FBU%^^!Z=_?,O0=#4G@6A?(U]>X]5&<+!N+;CU='9$.5 DPJ)+
M_37-90,\U'-%,-<S)%-^.",T*O:>"![O@E6,RG<%[252C\_G)E)$&QX7$1;9
M=/["L+N),)ZNB P1_1,CT6/1)5+8PAN45APY;-%._?#EJ6='P1V>$A,R4Y]1
M;"-NE56<MMV:G?31RY,NIMR1[M%"N-1<<;)E*W:BK]T1'6!!> 1/%W9=31AO
MF+/#/GYYV".!S*7\<!6/.;5 +K=7'.Z&&3O4-R\/=8C#1.A)JK<,9XA-,3#[
M6F451VRW9B?]UM4Z-T++?J2=D0G)2J[/23S& ESP('W%V3]CUIZ$$U=)T.5\
MS-E0:0/#F38K;Q-E"CAS1L(7U[MVJD4Z=MNVY^3454X&R9B2\(IRM%E\V36U
M(%XR!=0U+5>$KPC%HJO7\"D7< U95M6"\H8Q@+.# C(_S;(:ZP[/N5!FC=?,
M$@G/*W9Y+<A#5H$4.*LF^TQA$S5YQ/JB%>5A@BD Y+5( 6052(&#,C.+ZPNG
MB08FLK,3/OPW=;6 OF4.H.V@!,T"NL>47C.^8$.,)&<XZDN9[+BLA/2UH ^:
M!;+@H#;- AO.=&3F61%B\ );$M6"=]D6 -E!K9I'$R-*/R22,"SA::6LJ@?F
MLC& L[-*M1=C,=5K^D?!%VKVW%%M5]>".V 4X.^L2.TM1P(Q24P V2TX&/ZV
MM![D+18![ [JT$Z,690^FL0R%"0-P8+<*JLX;KLUX)&/LX*TST(N=.60HC*E
M ^YR?5DE5ET>P8^ =N]5\43\D'$@+\X*6'-1^\QMR35)+8BO6P+P.BM..U&D
M.<G\XT8O]VV0LTU;"^!6DP!Y9S5I'DU7?[T5(UU /,=]35DGZNL& >;.*M,\
MI'26NQ4#P1\)"^'9'9#7B?Z652 %SLK2/*X!EPK1O\A\Y_)J%=<)_X9- +Z#
M<M6<A1V!$8"[U%QQP&4K %('E:EY3Y4.9IS!UR=;DHJCW;8$X'50>-X+HA1F
MYCEAPO)'MK9;+'9=Q4$#Y@#:#NK-(:<D).:QR2>]8 B";"^U6$05YVRS!;SR
MYJ#2' AL,H[U0IR^+V9>6Q:WDXEU[M@AKCCT738!^ [*R8VHLMOT/Y6"[5WJ
ME0B+92 =#LK/I[M 5Q39WG,IMU<<](89@&I16KX+MHSHFO3A8B]O,'_,/Y-<
M[/T+4$L#!!0    ( (MU^5A:\ 4ZL#P  %?< 0 /    =71M9%]E>#DY>C$N
M:'1M[7U[<]M&LN__YU/,K94W5%T(QHLOV^LJ69)M;6);L>23/??4J5,@"8E8
M@P #@)*53W^[>V;P(BD"! C2B9/=2"*!F9Z>GIZ>GE]WOWI_\^&7U__QZO^<
MG+"K,)@LQLZ$C1[9Q?F[T\_1PHT=%@6W\8,=.@H[G=S;/CYP%LSFB]@)V:7O
M!_=V[ 9^I, ?8U6![^:/H7LWC5GG[)@9FC8X,33#8O]]=?6OG[OO?NOW]%^T
M_[QX>V/]?/[V?U3V\/"@.I,[.Z3>U'$P8R<G0-'[B]-S^/%<_'SSZ?R_X,?Y
MY7^R*'[TG'_,[/#.]4\\YS9^T3?F\<L'=Q)/7UB]P3Q^_>K]9_'83Z,@G#CA
M"^WEU$&JX!?^H/:2M_!"M^8QT_#?GUZ_NF*VY][Y_Q@[/HY/M'$;^/$+78?G
M;MR9$[&/S@/[',QL7[:!K[YY??&O]Y=O+F_8<*CJKYZ_>?WJ^160O'V3?_='
MT?SEYE:T381]N?EPSCX[\R",(_;6]6$67=MC5TYX&X0SG%,&O[!K9QSX,+NV
MY_@3.V2_+NP0.[/AP[=N&,7LO>W=,IS.='@WIV]^N1#T<%Z?C //L^>1\T+^
M(EBN:]JSUZ]N/L/_S]D]'T\<S,7+_)DN/G)5A4MG\(P]CE^P-Z%K^^SG()C#
M ZPST/1CUNWU3G000D[K\YOS$GWS+[D,5Z#CGPOOD1E=1? GZ>\Y#!A_13[1
M1&XM 15>O+:]F/UB?W78F1L_*NQ+;$_9W_\V,'3])6_T-&+ST+EW@T4$=,_#
MX-_..'8FXM$/SL0=HXB03HC%ZF;__=&.)O;O+QA*U/^PT %>_0$*(>*2,Y:2
M\[N0G([QZS&)SRV)SQ3%IZ._/R8>P8=2$D,G6G@@FP]3=SR%OVX]((;9+%J,
MHMCV8WQFXHP]UW>8Z\,#]XZ_<")U"\YLS=*S11@Z0"Y\#23$4S<".CS'CAP&
MVA'(\P/@'[,C=L1@,7VY/F?_8%_4:Y6=XS((HY?L] M^=KJ(XA 89Z=?_/UO
M>L\4$P/OOGMSA>_^S*Z"!3#O&E@)0[][R<ZHZ;-3;.;,]NT)2GS2"C(:YMCL
M66E3%U\^P[,7BS"(5":&\,CL&30,_(ZG8;"XFP:+6 X(=02-A\8(P@&-PNP[
MW\8.<&>.JF>*7\L6L,^'J0.?T/!5QGM^XXSM!7 FN(56'&04[!+W#DA:-,4>
MHCD0CE\"NY5D^E$)V?XCNX-'L?O0<4YF,#53[-@-)D@4;!!S.W2CP&</+GQC
M)V*\ZH69_8B$L1$."$4:J<".>3/\SVSW2.VC R(,\VC#R +/:57*7KW]]/$F
MOW>=C((X#F8O]/DWV(P]=\+^IM$_/[W^=.^$]RXT R/ZS$?QZCFV\+I-FB]]
M-@I=YU8!KOI$H8TK(0YB6+;&KWRQRS7+'E!8C@S%ZO5 %PQ5X]DQ\P+X%'@/
M0@%3S%\Q%3[!^OM" T>FTK/P74NUEM[E3YM2#F^F3E9Q1*"@Q/(%40%]%3MW
M08A+VODV]VSX8A8 ==082@(?0FY4O G1INSFM]]XH_"&/?(<$#>@"M8=:EP#
M+(X@]":PQSCTM[X-C[.3T_"6:QGJP*JZZU:3T\]\[D!G$<,?<T*Z85<V!FK7
M>E;'-+L"C0,F*BX2$*U?2%YN:&:KC8+,J&N<_XKT]XRFZ ?QW@W]W$I9)R@C
M>_SU+L3-""4M"%_\[>SLXN+MVY<U) C6S!58"\'-Q=E[]NGBPP9F;B"AOI3T
MM6>U2:@YT?W>L])34H/S9U,PO-B;JP_LW 53Q!TMXB!L:2T:^B8N-\5,W2C/
MS!W)]UO7BZ8NJ#W/G;/KQRAV9ON6\FH:0T>!+*/J=KXTJM%M=%?076T];7D*
M)+W\HJ7%I&O]UE:3;BXOIY8/M6!G!F!CA0SL*3R4V'=WH7-'5MD*$PT,,MOS
MQ!O\HXR]1U;H%&87FYLZR;G"O^/69AR0'8FM@)C)\P2<H:[XD2\"\Y%LQ8D3
MV[#,I0&)#0A+-3E7D#78ZBGBW(GFZ+M#BS2""7=OX>CCQW#\XM8RL4.A4SRS
MQZ"B[H%M\S"X=6/&6TGXY_K F9RI'+DS%PZ<R"(X(::'O#EP**3#$SD:^B_A
M41M>%:Q[<6!6;U\=5M3I+V/G6WP"YTA8/2_Z*CR:IW##(M1-51_4[U$<J"IS
M<U5;U;1JYW0>YIU(_USXQ^4VB)^R/'@IN@JY1U;M MF%OIKADOG]<JF7<(E<
MW#MADCA:[X-)_X03]I9,$CPRU*Y1?S4)?\$!LZ">Y5I=R_WT^ET81!&Z?G$[
M^$ ?L\Z[J^=\VSC>9-UL("E5@]O9(JLXW]/4C>>*GTK154XU-4PY:X#TDOJB
M.<J[0W58\\2<KN$&&:JK5N53]#:KY!/8-7:,]MXE-Y'D2OET67:E[&Y!F&:)
M!;%/N3>M_#0ULQLVRL"29ZM="#%P9]B<]V(;Z18R_<9B-_:W1+0OWMP<\"Y@
M@5A\G[L 4&XT07GKR\32-R_C/6P"14G8V2;PT8D+ZI^;<IV/R2;PZO(UK)7+
MDE;M;O:"C<*UP]X-M5>^]U[SBK2DPWDG:KRP"^_%:W;*HL4,_GR4?IKQU/;O
MZ#I4^':BV(Z=&= M/58*L\=CT"-HW,0!!S&\<WRP=SSOD9V.$0O@3/ 7! '@
M4U<AM.7.T<G6^7+-WIV>7ATK[#;PO.#AX#P_ ]5:L="?1E%5\/,8756K>4GR
M:[F.>O5$%D^_597D:MZ5G\N=\ZZZL\;UEH[A3B571/UYJ.XY6,""/EE#:3UK
M<9L9_BRQ&9WK)HS#^E+0T8?/CFL247M6.[J5(V)G"RSGL.F\NRIY\&R'S<UQ
MLU>!F[N0\J43/QSU#T#4#>,01+W?CJC+<ZESBY=O>#;%0^F?5."-/0M\YG0#
M!YH#$'4XG1R J%>9EAK<O[!#O$Z.$*?/K@EUV[FXNFY1UKLMRKJ^@JG)26G;
M<([TO;E]YYR,0L?^>F+? G$O;._!?HQ>%MLSY_'+91$::OBO[&* /61NWQ )
M>I+0(P<E+++M(U&JH$ZF=,V.?(=Q9A&OQJ]Y;$0*P[4C=@?\B"5X%M'/^GN\
MQ8=V73CGC02&.Y[*._R3.#@1P.I,%X0BX  +."RZ<2ZP8&;_&]H=N<$<!'AF
MCYU%3($%GRX^L/$B @L7^H>S8XBHB@F[#8,9.](5S>H1FO?7!(T!'_9-(X4'
M6RKOV \>$'OAC!&,GF 39O:=[\:+"8$3,K3B6#P[BEG\$,@HA4@>C"7N.^U#
M0M-QSX=/CWH,FO<0BYG!47 @A!OEQ[0.3"X<1$1[Z "KO]HCX%."PB#(!L(F
MWET)*$:&GAQU)@R,PSQ@4\H11!(.;W^E SQ(#700.AC(@9%:V *(S^+6'L<+
M0KP@__S(B52&@H3178C"'SD>DH2X>CL6,/ZD#<+/S&Q@,(*T,8 @LL<AXDRP
M0?B-3S.P+UB 7$;,=YP)3C"PQ0O\.Y0Z)YR!" 8/\51RY=.EG*Q)!HD-G)@L
M'!*"WF H43L2%T[>"0_ZNZ- -!#W*(DDX8$,8V^!7<.P4PON@@^9(AJ$PT)E
M[WG+?N"?!,F3PDDRHD@)SH>,0('Q@811? &C#PFT'J_ G<M!GHJY<B*8&EJ4
MHHL8K)EY&-R[$8X#N@<.\W$)N<BT^/%2H=B+#+I'1&:$SAPX/H7E% ';:'XE
MJZ:.-\<Y6(0$BJ+I=)9&='6=Q&MPT796@]XS2"A\INA,@F6566^H?_DZ2\),
M6D5$X7I+8$EX;F:FQD.UV!O;HQ"XZZD#]@YH2YCV!<+(XA $540A^ $,?Q2K
M[,(GM]B9'4UI BY]6"(Q'S /;1@,52/1$_"_?&\<9T;A$>QH:*C#[*/GSMB9
MC6!J3%U9BF,HM(,$C 3I7$MA]!&M_+G]B#0>&1E",'0&7YFX]^[$\2>DMD!7
MC;^"6H)]*5)2R:&7AZJ5DG9+>AUHG\%?])8BM38^C"N&6G\(0E(Z8QL4$ZS_
MT2,[TM1NTE"'KT:.D@/IHV<I*BF&U6./7%S(,(7\O8%\CP>1"84&7^CY8?&^
M2(M-0.N'2Y*_1F0E^R*<^<.2UZWB*R+6$7<.W"?$3BK"9B6TK/40HIOE0!NY
MY=%.F430L,YOOQVG"$^,LL-]I$)84;M!@S B-XI1O)-]0<1:"NG-*:;KBS.F
M:R<_BV!=)O;=D0/-$;0T8ZDH@@OP46)>H>4510O<F@.P?P): Q,PQG 'QB5D
MC^&WB.,XT;.?[3QCM8$)=0=:+6?1*&FX!J[]^\ 5L>*$CT6J:"<FG8C[AS]1
MQ*1PRZW3[ZMF,BD9FR:K$>4<L<X-!14^\,A"V6)J<'%:'-CCU[1TU-,&V5D_
M%BH 9XG6 2[KL>/>2ZLS#4:)QE/039ZP5G!DAMQ [7N<#0<,*->'S=LK&(AV
MHLSP#.$%=]1"+M(EFKISOEL(%<4-JYF-5T<AQ2AA3_#3GH.D?",3 :;DR.IJ
M*CN-UK6&0^58-L%U4^D/!P+C*PUDM.24Q&)#(\]/V*$P\U>:/4MP,VF;Q_5E
MQ3@QCQ] #<.A+PJ8 Q8LFD'V")L^TM5^P5:V(VF 9U'!1'?;JQ)W4["]Q()*
M>0AB\PF,P4D:%8.8<=QA\!R4-;5N/3"$%W9B3XNC!,Q3&I^*2&F?VU>/H*1\
M$DOB-5]?^!+8&K3?V1CMC)8Z-L:?@8=)R-P_H(G0A@F(:7HXH!UD"Z@D&YL,
MWJRA(**Q^=%+@M&EA2> W(^*,)'Q'$@3:$=I%/B28B*!*&@GA=X5EGG*1-1'
M7A!,5NJBSINK#\?L*QH3M.CDNB[J(JF ,$AI)F+1N1[+S@YP82P,:$9!37B
M@?TZ.82E<HLQ[IX]IB  $:1.)[-;]QN\+Q0"R3;2(;EYF3D)<M7#UU97 WUF
M#C/Z3+ !A,7Y!K.5\"-[7%M6=(EA\L7WW*].VIE97(-\I8E0YLR^9HJVY1DT
MPQV%P8_EU4R'HE3%\<,+K%<COUY;79"_\4AN/-DQ#P360RE:P.()8]"+E,
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M,+V_B6'+5W*;,"^'"R_+YHRMBBE+<DP= J8LP0SCFOKMM_4XLC(IIG]<\_U
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M&)NL3F)C59BQ"VLIAN4O9H\@+C"C+Y@-,A",OP(U BOHK'N<T![!R=CV//A
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M.O\O_/G^YL,OK__C_P-02P$"% ,4    " "+=?E8;IE7MFP.  #O80  $0
M            @ $     =71M9"TR,#(T,#<R-2YH=&U02P$"% ,4    " "+
M=?E8EA9EI\P"  #T"   $0              @ &;#@  =71M9"TR,#(T,#<R
M-2YX<V102P$"% ,4    " "+=?E85^8R%!@"   F!P  %0
M@ &6$0  =71M9"TR,#(T,#<R-5]D968N>&UL4$L! A0#%     @ BW7Y6!!3
M-+$M"   VDX  !4              ( !X1,  '5T;60M,C R-# W,C5?;&%B
M+GAM;%!+ 0(4 Q0    ( (MU^5C9DRLSJ04  $8T   5              "
M 4$<  !U=&UD+3(P,C0P-S(U7W!R92YX;6Q02P$"% ,4    " "+=?E86O %
M.K \  !7W $ #P              @ $=(@  =71M9%]E>#DY>C$N:'1M4$L%
3!@     &  8 A $  /I>      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>utmd-20240725_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20240725.xsd" xlink:type="simple"/>
    <context id="D240725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-07-25</startDate>
            <endDate>2024-07-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D240725" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D240725" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D240725" id="ixv-342">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D240725" id="ixv-343">2024-07-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D240725" id="ixv-344">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D240725" id="ixv-345">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D240725" id="ixv-346">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D240725" id="ixv-347">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D240725" id="ixv-348">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D240725" id="ixv-349">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D240725" id="ixv-350">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D240725" id="ixv-351">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D240725" id="ixv-352">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D240725" id="ixv-353">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D240725" id="ixv-354">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D240725" id="ixv-355">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D240725" id="ixv-356">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D240725" id="ixv-357">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D240725" id="ixv-358">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
